How CMTA’s Preclinical Toolbox helped move an early-stage CMT1A program forward
Through the CMTA Preclinical Toolbox, EverTree Bio (EverTree) conducted its first testing of an early-stage therapeutic approach for Charcot-Marie-Tooth disease type 1A (CMT1A). That early Toolbox work laid the foundation for CMTA’s $100,000 investment in the company, supporting the continuation of this cutting-edge work.
What Is the CMTA Preclinical Toolbox?
The CMTA Preclinical Toolbox is a set of CMT-specific research models and resources that enable early-stage programs to test therapeutic ideas before moving into more advanced development and clinical trials. By providing access to CMT models and scientific expertise, the Toolbox helps researchers generate early data, understand whether an approach is viable, and determine what next steps are needed to move forward.
Why This Work Matters
Early-stage CMT research often stalls not because the science fails, but because the resources needed to keep it moving are hard to access. When initial testing produces data that justify continued work, gaps in funding can slow progress at exactly the wrong moment.
From Early Testing to Investment
EverTree’s first engagement with CMTA took place through the CMTA Preclinical Toolbox.
That early work helped EverTree validate key aspects of its approach and established the basis for continuing the program.
Once that groundwork was in place, the challenge became sustaining the work. CMTA’s $100,000 investment helps bridge that gap, allowing the program to continue building on its early testing rather than stalling at an early stage.
“We’re proud to support science that targets the core biology of CMT1A in innovative ways,” said Sue Bruhn, PhD, CMTA CEO. “EverTree’s approach aligns with our mission to advance strong, patient-focused science that otherwise may be ignored. Our goal is to ensure promising programs like this continue moving forward and are not stalled by early-stage funding gaps.”
Continuing the Work
For EverTree, the investment supports continued development following its early Preclinical Toolbox work.
“CMTA has been a key partner from the beginning,” said Sarah Kishinevsky, PhD, EverTree Co-Founder and CEO. “Their early support helped us validate our ideas, and this investment allows us to build on that work. We’re excited to keep moving forward together.”
This progression reflects the way CMTA supports CMT-focused science. Early programs can access tools, expertise, and resources through the CMTA Preclinical Toolbox to test new ideas and generate initial data. When that work demonstrates patient-focused science and readiness to advance, CMTA can provide follow-on support, including targeted investment, to help programs continue moving forward rather than stalling at an early stage.
Read the full announcement here.
